TPBG and cancer: Furthermore, TPBG, a glycoprotein that inhibits the Wnt/β-catenin pathway and is associated with poor clinical outcomes in various cancer types [30,39,40,41], shows decreased expression following EPZ004777 treatment, which may contribute to the inhibition of cancer cell proliferation.